유럽 연합 - 그리스어 - EMA (European Medicines Agency)

mylan pharmaceuticals limited - deferasirox - iron overload; beta-thalassemia - Χηλικοί παράγοντες σιδήρου - deferasirox mylan ενδείκνυται για τη θεραπεία της χρόνιας υπερφόρτωσης σιδήρου που οφείλεται σε συχνές μεταγγίσεις αίματος (≥7 ml/kg/μήνα συμπυκνωμένων ερυθρών αιμοσφαιρίων) σε ασθενείς με μείζονα β-μεσογειακή αναιμία ηλικίας 6 ετών και olderthe θεραπεία της χρόνιας υπερφόρτωσης σιδήρου που οφείλεται σε μεταγγίσεις αίματος όταν η θεραπεία με δεφεροξαμίνη αντενδείκνυται ή είναι ανεπαρκής στις ακόλουθες ομάδες ασθενών:σε παιδιατρικούς ασθενείς με μείζονα β-μεσογειακή αναιμία με υπερφόρτωση σιδήρου που οφείλεται σε συχνές μεταγγίσεις αίματος (≥7 ml/kg/μήνα συμπυκνωμένων ερυθρών αιμοσφαιρίων) ηλικίας 2 έως 5 ετών,σε ενήλικες και παιδιατρικούς ασθενείς με μείζονα β-μεσογειακή αναιμία με υπερφόρτωση σιδήρου που οφείλεται σε συχνές μεταγγίσεις αίματος (.

유럽 연합 - 그리스어 - EMA (European Medicines Agency)

mylan ireland limited - αζακιτιδίνη - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Αντινεοπλασματικοί παράγοντες - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

유럽 연합 - 그리스어 - EMA (European Medicines Agency)

mylan ireland limited - λεναλιδομίδη - Πολλαπλό μυέλωμα - Ανοσοκατασταλτικά - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

유럽 연합 - 그리스어 - EMA (European Medicines Agency)

mylan ireland limited - οξική απιρατερόνη - Νεοπλάσματα του προστάτη - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

유럽 연합 - 그리스어 - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - Σακχαρώδης διαβήτης τύπου 2 - Φάρμακα που χρησιμοποιούνται στον διαβήτη - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. θεραπεία τριπλού συνδυασμού) ως επιπρόσθετο στη δίαιτα και την άσκηση σε ασθενείς που δεν ελέγχονται επαρκώς με μέγιστη ανεκτή για αυτούς δόση μετφορμίνης και σουλφονυλουρίας. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

유럽 연합 - 그리스어 - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - Η Σκλήρυνση Κατά Πλάκας, Υποτροπιάζουσα-Διαλείπουσα - Ανοσοκατασταλτικά - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

그리스 - 그리스어 - Εθνικός Οργανισμός Φαρμάκων

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - ezetimibe; simvastatin - tab (ΔΙΣΚΙΟ) - (10+10)mg/tab - ezetimibe 10mg; simvastatin 10mg - simvastatin and ezetimibe

그리스 - 그리스어 - Εθνικός Οργανισμός Φαρμάκων

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - ezetimibe; simvastatin - tab (ΔΙΣΚΙΟ) - (10+40)mg/tab - ezetimibe 10mg; simvastatin 40mg - simvastatin and ezetimibe

그리스 - 그리스어 - Εθνικός Οργανισμός Φαρμάκων

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - ezetimibe; simvastatin - tab (ΔΙΣΚΙΟ) - (10+20)mg/tab - ezetimibe 10mg; simvastatin 20mg - simvastatin and ezetimibe

그리스 - 그리스어 - Εθνικός Οργανισμός Φαρμάκων

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - levodopa; carbidopa monohydrate; entacapone - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (50+12.5+200)mg/tab - levodopa 50mg; carbidopa monohydrate 13,5mg; entacapone 200mg - levodopa, decarboxylase inhibitor and comt inhibitor